AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8106908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Etoposide (VP16) alternating with Cyclophosphamide + Epirubicin
Number of subjects: 113
Study 8106908 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide + Epirubicin + Vincristine
Number of subjects: 113
Study 3631561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (2 mg/min) started 30 min before operation and continued for 24 hr after surgery (n = 18)
Number of subjects: 38
Study 3631561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (2 mg/min)
Number of subjects: 38
Study 3631561 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (n = 20)
Number of subjects: 38
Study 31980545 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 161
Study 31980545 — intervention group
Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 161
Study 30134358 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed partner intimacy (female partner stressed)
Number of subjects: 366
Study 30134358 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed partner intimacy (male partner stressed)
Number of subjects: 366
Study 30134358 — intervention group
Group type: COMPARATOR
Intervention: Both partners stressed in parallel
Number of subjects: 366
Study 30134358 — intervention group
Group type: COMPARATOR
Intervention: Only the female partner stressed
Number of subjects: 366
Study 30134358 — intervention group
Group type: COMPARATOR
Intervention: Only the male partner stressed
Number of subjects: 366
Study 28674701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma desensitiser
Number of subjects: 68
Study 28674701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Relief
Number of subjects: 68
Study 28674701 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal F
Number of subjects: 68
Study 28674701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 68
Study 25413839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene measures and progressive muscle relaxation techniques for 4 weeks
Number of subjects: 16
Study 25413839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 23182410 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 19
Study 22099890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine via inferior alveolar nerve block (IANB)
Number of subjects: 0
Study 22099890 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine via buccal infiltration (B Infil)
Number of subjects: 0
Study 22099890 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine via inferior alveolar nerve block (IANB)
Number of subjects: 0
Study 18306855 — intervention group
Group type: EXPERIMENTAL
Intervention: MVE ceramide-containing liquid cleanser and moisturizing cream plus fluocinonide cream 0.05%
Number of subjects: 0
Study 18306855 — intervention group
Group type: COMPARATOR
Intervention: Bar cleanser plus fluocinonide cream 0.05%
Number of subjects: 0
Study 17181872 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily water intake by 1 litre/d
Number of subjects: 94
Study 17181872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested 1 litre blueberry juice/d
Number of subjects: 94
Study 17181872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no increased fluid intake)
Number of subjects: 94
Study 14530832 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Burch procedure (n=19)
Number of subjects: 36
Study 14530832 — intervention group
Group type: COMPARATOR
Intervention: Sling placement (n=17)
Number of subjects: 36
Study 11126099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes
Number of subjects: 0
Study 8765618 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose RSVIG (750 mg/kg monthly)
Number of subjects: 249
Study 8765618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose RSVIG (150 mg/kg monthly)
Number of subjects: 249
Study 8765618 — intervention group
Group type: COMPARATOR
Intervention: Control (no RSVIG)
Number of subjects: 249
Study 1544195 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.075 mg.kg-1
Number of subjects: 90
Study 1544195 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol plus P6 acupuncture
Number of subjects: 90
Study 1544195 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupuncture alone
Number of subjects: 90
Study 1544195 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 90
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) solution
Number of subjects: 0
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Number of subjects: 0
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate derivatives
Number of subjects: 0
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Other calcium antagonists
Number of subjects: 0
Study 2865926 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 30586011 — intervention group
Group type: EXPERIMENTAL
Intervention: Defect-closing group (barbed suture)
Number of subjects: 60
Study 30586011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30586011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 30558556 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchscreen device
Number of subjects: 30
Study 30558556 — intervention group
Group type: COMPARATOR
Intervention: Finger Motion control device
Number of subjects: 30
Study 30558556 — intervention group
Group type: COMPARATOR
Intervention: Motion tracking device
Number of subjects: 30
Study 26913407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (DC-CIK + chemotherapy)
Number of subjects: 42
Study 26913407 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy group
Number of subjects: 42
Study 25145762 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal of urinary catheter after elective cesarean section
Number of subjects: 300
Study 25145762 — intervention group
Group type: COMPARATOR
Intervention: Delayed removal of urinary catheter 12 h postoperatively
Number of subjects: 300
Study 22296865 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment
Number of subjects: 60
Study 22296865 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 20726278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electrical stimulation of the vestibular apparatus at a frequency of 0.5 Hz
Number of subjects: 198
Study 20726278 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 198
Study 18407311 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient singleton color distractor present on a small proportion of trials
Number of subjects: 0
Study 18407311 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient singleton color distractor present on a large proportion of trials
Number of subjects: 0
Study 18407311 — intervention group
Group type: COMPARATOR
Intervention: No distractor trials
Number of subjects: 0
Study 15812748 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital initiation of carvedilol
Number of subjects: 567
Study 15812748 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of postdischarge beta-blocker initiation
Number of subjects: 567
Study 12873840 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback group
Number of subjects: 20
Study 12873840 — intervention group
Group type: COMPARATOR
Intervention: No-feedback group
Number of subjects: 20
Study 10328319 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop in palliative cancer care for general practitioners
Number of subjects: 120
Study 7547047 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 39
Study 7547047 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 39
Study 8444273 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 7
Study 8444273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3018566 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 150 mg daily
Number of subjects: 42
Study 3018566 — intervention group
Group type: COMPARATOR
Intervention: Enalapril, 40 mg daily
Number of subjects: 42
Study 29984884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive therapy (target SBP < 120 mm Hg)
Number of subjects: 8884
Study 29984884 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive therapy (target SBP < 140 mm Hg)
Number of subjects: 8884
Study 29984884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (intensive and standard)
Number of subjects: 8884
Study 29984884 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit DBP variability
Number of subjects: 8884
Study 26318982 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar transurethral prostate resection
Number of subjects: 279
Study 26318982 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral prostate resection
Number of subjects: 279
Study 24633589 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training at low 12 Hz frequency, 10 weeks, twice-a-week
Number of subjects: 15
Study 24633589 — intervention group
Group type: COMPARATOR
Intervention: Sham training without vibration
Number of subjects: 15
Study 23156119 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified wheat meal
Number of subjects: 179
Study 23156119 — intervention group
Group type: COMPARATOR
Intervention: Control meal without added iron
Number of subjects: 179
Study 20237125 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (mean dose 4.4 mg/kg per infusion, administered every 8 weeks)
Number of subjects: 78
Study 20237125 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 78
Study 18294029 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (SWL) using Modulith SLX Classic and Modulith SLX‐F2 lithotripters
Number of subjects: 598
Study 18294029 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (SWL)
Number of subjects: 598
Study 16187871 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cortisol
Number of subjects: 85
Study 16187871 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 85
Study 16187871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 16187871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg and 40 mg)
Number of subjects: 85
Study 12562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (N=27)
Number of subjects: 101
Study 12562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (N=25)
Number of subjects: 101
Study 12562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (N=22)
Number of subjects: 101
Study 12562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (N=26)
Number of subjects: 101
Study 12562575 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (N=101)
Number of subjects: 101
Study 9442160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 278
Study 9442160 — intervention group
Group type: COMPARATOR
Intervention: Routine pelvic examination (Control)
Number of subjects: 278
Study 8031553 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/day)
Number of subjects: 57
Study 8031553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2721846 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills oriented training
Number of subjects: 24
Study 2721846 — intervention group
Group type: COMPARATOR
Intervention: Sexual awareness oriented training
Number of subjects: 24
Study 1098684 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 81
Study 1098684 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 81
Study 1098684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 81
Study 1098684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 81
Study 31318997 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified for diabetes mellitus (DM) in idiopathic chronic pancreatitis (ICP) patients: adult at onset of ICP, biliary stricture at/before diagnosis of CP, steatorrhea at/before diagnosis of CP, complex pathologic changes in main pancreatic duct.
Number of subjects: 1633
Study 31318997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed based on training cohort.
Number of subjects: 1633
Study 31383430 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Cranial Therapy (MC-t)
Number of subjects: 50
Study 31383430 — intervention group
Group type: COMPARATOR
Intervention: Massage Therapy (Mss-t)
Number of subjects: 50
Study 29077724 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based aftercare case management (ACM) consisting of six phone contacts at two-week intervals by trained psychotherapists.
Number of subjects: 199
Study 29077724 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 199
Study 26164391 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent vegan and vegetarian participants (n=16)
Number of subjects: 38
Study 26164391 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent vegan/vegetarian participants (n=16)
Number of subjects: 38
Study 26164391 — intervention group
Group type: COMPARATOR
Intervention: All diet groups (vegan, vegetarian, pesco-vegetarian, semi-vegetarian, omnivore)
Number of subjects: 38
Study 23187069 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychological intervention based on cognitive behavioral therapy and motivational interviewing
Number of subjects: 0
Study 23187069 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 21999295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at self‐selected intensity, expending 700 kcal per session for men and 500 kcal per session for women
Number of subjects: 34
Study 21999295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intensity
Number of subjects: 34
Study 18061271 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and intracameral anesthesia (supplementary intracameral lidocaine)
Number of subjects: 1281
Study 18061271 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 1281
Study 17243547 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride with calcium and vitamin D3
Number of subjects: 254
Study 17243547 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D3
Number of subjects: 254
Study 12777909 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab)
Number of subjects: 110
Study 12777909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study 10700898 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT oral administration for one year at 3-4 capsules daily
Number of subjects: 435
Study 10700898 — intervention group
Group type: COMPARATOR
Intervention: CDDP i.p. administration of 70 mg/m2 at the time of resective surgery
Number of subjects: 435
Study 9118155 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 15
Study 9118155 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 15
Study 9118155 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 15
Study 8251021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 ml per day containing 3.1 g of omega-3 fatty acids)
Number of subjects: 20
Study 8251021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3693871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 0
Study 3693871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (2.5 mg)
Number of subjects: 0
Study 3693871 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 0
Study 3693871 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study 30009424 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (R-maintenance group)
Number of subjects: 396
Study 30009424 — intervention group
Group type: COMPARATOR
Intervention: Observation group (no rituximab maintenance)
Number of subjects: 396
Study 26687902 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy (54 Gy/36f/12 days to 57.6 Gy, 61.2 Gy, and 64.8 Gy)
Number of subjects: 18
Study 26687902 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy
Number of subjects: 18
Study 26687902 — intervention group
Group type: COMPARATOR
Intervention: CHART radiotherapy
Number of subjects: 18
Study 26652081 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for spouses about supportive behaviors to control premenstrual symptoms during three educational sessions.
Number of subjects: 100
Study 26652081 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for spouses about supportive behaviors to control premenstrual symptoms.
Number of subjects: 100
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent palliative care
Number of subjects: 0
Study 23001893 — intervention group
Group type: COMPARATOR
Intervention: Usual cancer care
Number of subjects: 0
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint modeling approach (terminal decline model)
Number of subjects: 0
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecewise linear random intercept model
Number of subjects: 0
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecewise exponential model
Number of subjects: 0
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimators
Number of subjects: 0
Study 23001893 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years (QALY)
Number of subjects: 0
Study 20564593 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U per patient)
Number of subjects: 0
Study 20564593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting harm in the main text
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant harm in the main text
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract when harm is reported in the main text
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting harm in the abstract when statistically significant harm is reported in the main text
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood of reporting harm in the abstract when statistically significant harm is reported in the main body
Number of subjects: 363
Study 18371200 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood of reporting harm in the abstract when funded by drug companies
Number of subjects: 363
Study 16330205 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-M-VAC
Number of subjects: 263
Study 16330205 — intervention group
Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 263
Study 12810489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6‐ to 12‐mg/d
Number of subjects: 88
Study 12810489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 11184213 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led health education
Number of subjects: 0
Study 11184213 — intervention group
Group type: COMPARATOR
Intervention: Adult-led health education
Number of subjects: 0
Study 8779365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg‐1 premedication
Number of subjects: 40
Study 8779365 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 0.1 mg.kg‐1
Number of subjects: 40
Study 2022674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 0.2% in silver sulfadiazine 1%
Number of subjects: 253
Study 2022674 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine 1% alone
Number of subjects: 253
Study 2022674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4% during daily dressing changes
Number of subjects: 253
Study 2022674 — intervention group
Group type: COMPARATOR
Intervention: Nonantibacterial soap
Number of subjects: 253
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP (fluorouracil, cytoxan and prednisone)
Number of subjects: 126
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (fluorouracil, cytoxan and Adriamycin)
Number of subjects: 126
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: CA (cytoxan and Adriamycin)
Number of subjects: 126
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP-CA (alternating combinations of CFP and CA)
Number of subjects: 126
Study 7074523 — intervention group
Group type: COMPARATOR
Intervention: CFP-CA
Number of subjects: 126
Study 7074523 — intervention group
Group type: COMPARATOR
Intervention: CA
Number of subjects: 126
Study 7074523 — intervention group
Group type: COMPARATOR
Intervention: Adrenalectomy
Number of subjects: 126
Study 7074523 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 126
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (after adrenalectomy)
Number of subjects: 126
Study 7074523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy (after tamoxifen)
Number of subjects: 126